Outcomes of stereotactic body radiotherapy for large lung lesions: Is tumor size still a limiting factor?
Radiation Sciences in Oncology · 2026
DOI: 10.33066/rso.2026.18 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiation Sciences in Oncology, 2026. Verfasst von Pantea Bayatfard und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Evidence regarding stereotactic body radiotherapy (SBRT) for large lung lesions remains limited because most prospective trials excluded tumors ≥5 cm owing to concerns regarding treatment-related adverse events (AEs). We evaluated the efficacy and safety of SBRT in patients with large (≥4 cm) primary lung lesions. Materials and Methods: We retrospectively analyzed 29 consecutive patients with lung lesions ≥4 cm who underwent SBRT between 2020 and 2024. Clinical outcomes included radiologic response per RECIST v1.1, locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), overall survival (OS), recurrence patterns, and treatment-related AEs graded per CTCAE v5.0. Survival outcomes were estimated using the Kaplan–Meier method.
Results
The median tumor diameter was 45 mm (range: 40–57 mm), and the median prescribed dose was 50 Gy (range: 45–60 Gy) delivered in 5 fractions (range: 4–15 fractions). Histopathological confirmation was available in 66% of patients; the remaining 34% were clinically diagnosed based on radiologic and multidisciplinary evaluation. The median biologically effective dose (BED10) was 100 Gy (range: 84–150 Gy). After a median follow-up of 32 months (range: 3–64), the objective response rate was 69%, with complete and partial responses in 7% and 62% of patients, respectively. Local recurrence occurred in 10% of patients, while regional recurrence and distant metastasis were observed in 31% and 10%, respectively. The median LRFS, DMFS, and OS were not reached. The restricted mean LRFS, DMFS, and OS were 44.5, 56.9, and 51.8 months, respectively. On univariate analysis, no clinicopathologic or treatment-related variables were significantly associated with LRFS or OS. Treatment was well tolerated, with no Grade ≥3 AE and Grade 2 AE observed in only one patient (3.5%).
Conclusions
SBRT achieved favorable local tumor control with minimal AE in patients with ≥4 cm lung lesions. These findings suggest that SBRT is a safe and effective treatment strategy for carefully selected patients with large lung lesions when individualized treatment planning and adherence to organ-of-interest dose constraints are prioritized.
Zitieren
APA
Bayatfard, P., Sucak, İ., & Akyürek, S. (2026). Outcomes of stereotactic body radiotherapy for large lung lesions: Is tumor size still a limiting factor?. Radiation Sciences in Oncology. https://doi.org/10.33066/rso.2026.18
Vancouver
Bayatfard P, Sucak İ, Akyürek S. Outcomes of stereotactic body radiotherapy for large lung lesions: Is tumor size still a limiting factor?. Radiation Sciences in Oncology. 2026. doi:10.33066/rso.2026.18
BibTeX
@article{Bayatfard2026,
author = {Bayatfard, Pantea and Sucak, İpek and Akyürek, Serap},
title = {Outcomes of stereotactic body radiotherapy for large lung lesions: Is tumor size still a limiting factor?},
journal = {Radiation Sciences in Oncology},
year = {2026},
doi = {10.33066/rso.2026.18}
}
EUVIMED